“US Prostate Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Prostate Cancer. Research report covers all the ongoing drugs being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Prostate Cancer drug market based upon development process. For Report Sample Contact: rajesh@pnspharma.com

1. US Prostate Cancer Drug Pipeline Analysis
Prostate cancer has emerged as one of the most commonly diagnosed cancer among men in
the US. According to the American Cancer Society, there were close to 242,000 new cases of
prostate cancer in the US in 2012, with 28,000 men dying from it. This was an increase from
206,640 men diagnosed with the condition during 2009. The number of men being actively
treated for prostrate disorders such as benign prostatic hyperplasia (BPH), prostate cancer,
and prostatitis, is on a rise in the recent years. The continuous efforts and investment being
directed by the pharmaceutical companies is expected to reduce the incidence rate
significantly in the next 5 year horizon.
“US Prostate Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on
the various drugs being developed for the treatment of Prostate Cancer. Research report
covers all the ongoing drugs being developed in various clinical development phases. This
report enables pharmaceutical companies, collaborators and other associated stake holders to
identify and analyze the available investment opportunity in the Prostate Cancer drug market
based upon development process.
For Report Sample Contact: rajesh@pnspharma.com
Following parameters for each drug profile in development phase are covered in “US Prostate
Cancer Drug Pipeline Analysis” research report:
• Drug Profile Overview
• Alternate Names for Drug
• Active Indication
• Phase of Development
• Mechanism of Action
• Brand Name
• Patent Information
• Country for Clinical Trial
• Owner / Originator/ Licensee/Collaborator
• Administrative Route

2. • Drug Class
• ATC Codes
US Prostate Cancer Drug Pipeline by Clinical Phase:
• Research: 11
• Preclinical: 44
• Unknown Phase: 4
• Phase 0: 1
• Phase-I: 22
• Phase-I/II: 18
• Phase-II: 53
• Phase-II/III: 1
• Phase-III:14
• Marketed: 13
For Report Sample Contact: rajesh@pnspharma.com
Each Drug Profile has Tables Representing Following Information:
• Alternate Names
• Originator & Owner
• Collaborator
• Technology Provider
• Licensee
• Highest Development Phase
• Indications
• Class
• Mechanism of Action
• ATC Code
• Designated Brand Name